Cambridge Investment Research Advisors
AMED

Cambridge Investment Research Advisors’s Amedisys AMED Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,101
Closed -$305K – 3720
2025
Q2 		$305K Buy
+3,101
New +$293K ﹤0.01% 2962
2022
Q4 		– Sell
-2,944
Closed -$285K – 3106
2022
Q3 		$285K Sell
2,944
-476
-14% -$56.8K ﹤0.01% 2399
2022
Q2 		$360K Sell
3,420
-5
-0.1% -$639 ﹤0.01% 2215
2022
Q1 		$590K Buy
3,425
+620
+22% +$92.6K ﹤0.01% 1969
2021
Q4 		$454K Buy
2,805
+262
+10% +$42.1K ﹤0.01% 2183
2021
Q3 		$379K Buy
2,543
+115
+5% +$23.9K ﹤0.01% 2264
2021
Q2 		$595K Sell
2,428
-780
-24% -$205K ﹤0.01% 1919
2021
Q1 		$849K Buy
3,208
+547
+21% +$154K ﹤0.01% 1543
2020
Q4 		$781K Buy
2,661
+26
+1% +$6.67K ﹤0.01% 1468
2020
Q3 		$623K Buy
2,635
+1,021
+63% +$232K ﹤0.01% 1461
2020
Q2 		$320K Buy
1,614
+35
+2% +$6.53K ﹤0.01% 1840
2020
Q1 		$290K Sell
1,579
-97
-6% -$17.3K ﹤0.01% 1700
2019
Q4 		$280K Buy
+1,676
New +$249K ﹤0.01% 1953
2019
Q1 		– Sell
-8,712
Closed -$1.02M – 2279
2018
Q4 		$1.02M Buy
8,712
+48
+0.6% +$5.66K 0.01% 924
2018
Q3 		$1.08M Sell
8,664
-5,468
-39% -$604K 0.01% 980
2018
Q2 		$1.21M Buy
14,132
+783
+6% +$57.5K 0.01% 883
2018
Q1 		$805K Buy
+13,349
New +$760K 0.01% 1057
2017
Q3 		– Sell
-10,735
Closed -$674K – 1998
2017
Q2 		$674K Buy
+10,735
New +$625K 0.01% 1024

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cambridge Investment Research Advisors's AMED Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Amedisys (AMED) in Q3 2025, closing a stake of 3,101 shares — an estimated $305K sold.

Cambridge Investment Research Advisors first reported a position in AMED in Q2 2017 and held it in 18 quarters. The position peaked at $1.21M in Q2 2018. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Cambridge Investment Research Advisors reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 3,101 Amedisys shares in Q3 2025, an estimated $305K.
  • Cambridge Investment Research Advisors first reported a position in Amedisys in Q2 2017 and held it in 18 quarters.
  • Cambridge Investment Research Advisors's Amedisys position peaked at $1.21M in Q2 2018.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.